Once again racavalli is correct. The filing of the letter regarding the progress at Luoxis should be catapulting the stock upward. Clearly some entity or entities desiring to acquire more stock are trying to push the price down. Who could blame them? It's a trader's dream stock (low cap, no banker, etc.). Terrific but at this price.
Days like today are not fun, but neither is a dilution. Of course, the tradeoff is a market maker with vested interest. The company may be trying to enter negotiations from a position of strength, which the clinical data provide for the 2 main products.
Luoxis may provide a source of cash-flow, but as a diagnostic, is valued lower than new drugs by most investors. If they can corner the sepsis diagnosis market, that would be a major event.
Current Optina data is not sufficient to predict it's value vs competitive treatments. Ampion has huge potential and is clearly not in the price, even with an updated net present value number. Perhaps analyst upgrades may propel shares higher, especially once the final Ampion trial is announced.
Buffet is famous for stating "As a long-term investor, why do you want the price to go up?"